Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14132974 | 0.92 | GRM5 (0.85) | GRM5LMNA | |
| SCHEMBL14132564 | 0.91 | GRM5 (0.91) | GRM5LMNA | |
| SCHEMBL5924170 | 0.91 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL5924104 | 0.89 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL3677412 | 0.88 | GRM5 (0.80) | GRM5LMNA | |
| SCHEMBL14132972 | 0.87 | GRM5 (0.77) | GRM5LMNA | |
| SCHEMBL1821818 | 0.87 | GRM5 (0.76) | GRM5LMNA | |
| SCHEMBL5924064 | 0.86 | GRM5 (1.00) | GRM5LMNA | |
| SCHEMBL1823352 | 0.86 | GRM5 (1.00) | GRM5 | |
| SCHEMBL29681972 | 0.86 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416123-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2016-08-16 | — | — | US | disclosed |
| US-20150141462-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8853392-B2 | Benzamide mGluR5 positive allosteric modulators and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2013188465-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING DRUG ADDICTION AND PREVENTING A DRUG RELAPSE | ARIZONA BOARD OF REGENTS, FOR AND ON BEHALF OF, ARIZONA STATE UNIVERSITY (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013046041-A1 | PYRIDINYLPYRAZOLES FOR USE AS KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-04-04 | — | — | WO | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | THE TRUSTEES OF DARTMOUTH COLLEGE | 2012-11-29 | — | — | US | disclosed |
| EP-2276759-B1 | 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES | LILLY CO ELI (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2162136-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7531541-B2 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | VANDERBILT UNIVERSITY | 2007-09-06 | — | — | US | disclosed |
| WO-2007035823-A2 | PARTIAL MGLUR5 ANTAGONISTS AND METHODS OF USE THEREOF | MOLECULAR NEUROIMAGING, LLC (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20060281803-A1 | Pyrazole modulators of metabotropic glutamate receptors | MERCK & CO., INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2005030128-A2 | PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | GRM5 1/4885LMNA 4804/4885 |
| US-20140336225-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | DCK, MAP3K2, MAP3K19 | GRM5 1047/4885LMNA 4606/4885 |
| US-20060281803-A1 | Pyrazole modulators of metabotropic glutamate receptors | GRM5, GRM3, GRIK5 | GRM5 1/4885LMNA 4843/4885 |
| US-20070208028-A1 | Partial mGluR5 antagonists for treatment of anxiety and CNS disorders | GRM5, GRIK5, GRM1 | GRM5 1/4885LMNA 4484/4885 |
| US-20120302581-A1 | Methods and Compositions for the Treatment of RAS Associated Disorders | NRAS, HRAS, KRAS | GRM5 2702/4885LMNA 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.